Xtandi demonstrates significant improvement in OS in nmCRPC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III PROSPER trial, which evaluated Xtandi (enzalutamide) plus androgen deprivation therapy versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, demonstrated a statistically significant improvement in overall survival in patients with nmCRPC who were treated with Xtandi plus ADT.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login